OBJECTIVE: This study compared clinical outcomes of patients receiving CryoValve SG decellularized pulmonary valves with those of patients receiving conventionally processed CryoValve pulmonary valves. METHODS: All consecutive patients undergoing Ross procedures and right ventricular outflow tract reconstructions with SG valves at 7 institutions (February 2000-November 2005) were assessed retrospectively (193 Ross procedures, 149 right ventricular outflow tract reconstructions). Patient, procedural, and outcome data were compared with those from 1246 conventional implants (665 Ross procedures, 581 right ventricular outflow tract reconstructions). Hemodynamic function was assessed at latest follow-up. RESULTS: Follow-up was complete for 99% in SG group and 94% in conventional group, with mean follow-ups of 4.0 years (range, 0-6.7 years) for SG and 3.7 years (range, 0-6.7 years) for conventional. Five-year cumulative survivals and freedoms from adverse events were comparable between SG and conventional valves. Among patients undergoing Ross procedures, peak gradient at last follow-up was lower with SG valves (P < .01); no difference was observed in the right ventricular outflow tract reconstruction population. Pulmonary insufficiency was significantly reduced with SG valves in patients undergoing both Ross procedures (P < .01) and right ventricular outflow tract reconstructions (P < .01). Valve type was not a significant predictor of valve-related failure in propensity-adjusted analysis of either procedure. CONCLUSIONS: CryoValve SG decellularized pulmonary valves have acceptable clinical outcomes and favorably compare with conventionally processed valves. Improved hemodynamic function observed with SG valves could signify improved long-term outcomes and may be due to the decreased antigenicity of these valves. Published by Mosby, Inc.
OBJECTIVE: This study compared clinical outcomes of patients receiving CryoValve SG decellularized pulmonary valves with those of patients receiving conventionally processed CryoValve pulmonary valves. METHODS: All consecutive patients undergoing Ross procedures and right ventricular outflow tract reconstructions with SG valves at 7 institutions (February 2000-November 2005) were assessed retrospectively (193 Ross procedures, 149 right ventricular outflow tract reconstructions). Patient, procedural, and outcome data were compared with those from 1246 conventional implants (665 Ross procedures, 581 right ventricular outflow tract reconstructions). Hemodynamic function was assessed at latest follow-up. RESULTS: Follow-up was complete for 99% in SG group and 94% in conventional group, with mean follow-ups of 4.0 years (range, 0-6.7 years) for SG and 3.7 years (range, 0-6.7 years) for conventional. Five-year cumulative survivals and freedoms from adverse events were comparable between SG and conventional valves. Among patients undergoing Ross procedures, peak gradient at last follow-up was lower with SG valves (P < .01); no difference was observed in the right ventricular outflow tract reconstruction population. Pulmonary insufficiency was significantly reduced with SG valves in patients undergoing both Ross procedures (P < .01) and right ventricular outflow tract reconstructions (P < .01). Valve type was not a significant predictor of valve-related failure in propensity-adjusted analysis of either procedure. CONCLUSIONS: CryoValve SG decellularized pulmonary valves have acceptable clinical outcomes and favorably compare with conventionally processed valves. Improved hemodynamic function observed with SG valves could signify improved long-term outcomes and may be due to the decreased antigenicity of these valves. Published by Mosby, Inc.
Authors: José Rodolfo Paniagua Gutierrez; Helen Berry; Sotirios Korossis; Saeed Mirsadraee; Sergio Veiga Lopes; Francisco da Costa; John Kearney; Kevin Watterson; John Fisher; Eileen Ingham Journal: Tissue Eng Part A Date: 2014-10-01 Impact factor: 3.845
Authors: Johannes Jacobus van den Heever; Christiaan Johannes Jordaan; Angelique Lewies; Dreyer Bester; Jacqueline Goedhals; Lezelle Botes; Pascal Maria Dohmen; Francis Edwin Smit Journal: Cell Tissue Bank Date: 2021-08-28 Impact factor: 1.522
Authors: Tayyebeh Vafaee; Fiona Walker; Dan Thomas; João Gabriel Roderjan; Sergio Veiga Lopes; Francisco DA da Costa; Amisha Desai; Paul Rooney; Louise M Jennings; John Fisher; Helen E Berry; Eileen Ingham Journal: J Tissue Eng Date: 2022-06-28 Impact factor: 7.940
Authors: Tayyebeh Vafaee; Daniel Thomas; Amisha Desai; Louise M Jennings; Helen Berry; Paul Rooney; John Kearney; John Fisher; Eileen Ingham Journal: J Tissue Eng Regen Med Date: 2017-05-12 Impact factor: 3.963